These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20414917)

  • 1. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
    ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
    [No Abstract]   [Full Text] [Related]  

  • 2. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Xu B; Feng Y; Peng K; Xu G; Du J; Zhang L; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6877-81. PubMed ID: 19896374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
    J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.
    Ding Y; Mao L; Xu D; Xie H; Yang L; Xu H; Geng W; Gao Y; Xia C; Zhang X; Meng Q; Wu D; Zhao J; Hu W
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2744-8. PubMed ID: 26026363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
    Koga Y; Sakamaki S; Hongu M; Kawanishi E; Sakamoto T; Yamamoto Y; Kimata H; Nakayama K; Kuriyama C; Matsushita Y; Ueta K; Tsuda-Tsukimoto M; Nomura S
    Bioorg Med Chem; 2013 Sep; 21(17):5561-72. PubMed ID: 23809172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization.
    Robinson RP; Mascitti V; Boustany-Kari CM; Carr CL; Foley PM; Kimoto E; Leininger MT; Lowe A; Klenotic MK; Macdonald JI; Maguire RJ; Masterson VM; Maurer TS; Miao Z; Patel JD; Préville C; Reese MR; She L; Steppan CM; Thuma BA; Zhu T
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1569-72. PubMed ID: 20149653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
    Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
    Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
    Ellsworth BA; Meng W; Patel M; Girotra RN; Wu G; Sher PM; Hagan DL; Obermeier MT; Humphreys WG; Robertson JG; Wang A; Han S; Waldron TL; Morgan NN; Whaley JM; Washburn WN
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4770-3. PubMed ID: 18707880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
    Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
    Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
    Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
    J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2009 Nov; 19(11):1485-99. PubMed ID: 19852718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
    Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
    Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.
    Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Wu SH; Huang CY; Huang YL; Wang MH; Liu YW; Tsai CH; Kumar CR; Lee JC
    Eur J Med Chem; 2012 Sep; 55():32-8. PubMed ID: 22818040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
    Washburn WN
    J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
    Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.